Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: A systematic review and meta-analysis

Annals of Oncology

Volumn 26, Issue 3, 2015, Pages 477-485

  Berry, Scott R ^a   Cosby, R ^b   Asmis, T ^c   Chan, K ^a   Hammad, N ^d   Krzyzanowska, M K ^e  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Continuous chemotherapy; Intermittent chemotherapy; Meta analysis; Metastatic colorectal cancer; Systematic review

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM MAGNESIUM); BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ANEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS CHEMOTHERAPY; CONTROLLED STUDY; DISTRESS SYNDROME; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; FATIGUE; HAMILTON DEPRESSION RATING SCALE; HAND FOOT SYNDROME; HAZARD RATIO; HEMATOLOGIC DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAINTENANCE CHEMOTHERAPY; META ANALYSIS; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RASH; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MULTIMODALITY CANCER THERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84938746812     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu272     Document Type: Review

References (28)

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.10 [Internet]. Lyon, France: International Agency for Research on Cancer 2010. http://globocan.iarc.fr (2 December 2013, date last accessed).
2. Cunningham D, Atkin W, Lenz H-J et al. Colorectal cancer. Lancet Oncol 2010; 375: 1030-1047.
3. Review Manager (RevMan) [Computer program]. Version 5.1 for Windows. Copenhagen: the Nordic Cochrane Centre, The Cochrane Collaboration; 2011.
4. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. [Erratum appears in Stat Med. 2004; 23(11): 1817]. Stat Med 1998; 17: 2815-2834.
5. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361: 457-464.
6. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24: 394-400.
7. Grothey A, Hart LL, Rowland KM et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 2008; 26(15 suppl): 4010.
8. Alexopoulos CG, Kotsori AA. Continuous versus intermittent chemotherapy in metastatic colorectal cancer. J Clin Oncol 2006; 24(18 suppl): 3582.
9. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27: 5727-5733.
10. Adams RA, Meade AM, Seymour MT et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12: 642-653.
11. Labianca R, Sobrero A, Isa L et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol 2011; 22: 1236-1242.
12. Koopman M, Simkens L, May A et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 2014; 32(3 suppl): LBA388.
13. Diaz-Rubio E, Gomez-Espana A, Massuti B et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012; 17: 15-25.
14. Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762.
15. Yalcin S, Uslu R, Dane F et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'stop and go' study results-a Turkish Oncology Group trial. Oncology 2013; 85: 328-335.
16. De Gramont A, Bosset JF, Milan C et al. Randomzied trial comparing monthly low-dose leucovorin and fluorouracit bolus with bimonthly high-dose leucovorin and fluorouracit bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup trial. J Clin Oncol 1997; 15: 808-815.
17. Lokich JJ, Ahlgren JD, Cantrell J et al. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. Cancer 1991; 67: 14-19.
18. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
19. Punt CJA, Simkens LHJ, May A et al. Updated results including quality of life of the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG): maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). Eur J Cancer 2013; 49(2 suppl): S486.
20. Pereira AAL, Rego JFM, Hoff PM et al. The effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer: a meta-analysis of randomized trials. J Clin Oncol 2014; 32 (Suppl 5): 3542.
21. Wasan H, Adams RA, Wilson RH et al. Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): results of the two-arm phase II randomized MRC COIN-B trial. J Clin Oncol 2012; 30(4_suppl): 536.
22. Kay A, Yun L, Taback N, Krzyzanowska MK. Use and impact of chemotherapy-free intervals in metastatic colorectal cancer in routine practice. J Clin Oncol 2013; 31 (15_suppl): 6535.
23. Allegra C, Blanke C, Buyse M et al. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol 2007; 25: 3572-3575.
24. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142.
25. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. [Erratum appears in Lancet. 2007; 370: 566]. Lancet 2007; 370: 143-152.
26. Ducreux M, Malka D, Mendiboure J et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011; 12: 1032-1044.
27. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
28. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.